Get started
Markets US Stocks Health Technology Pharmaceuticals: Major

Cellectar Biosciences, Inc CLRB

CLRB NASDAQ
CLRB
Cellectar Biosciences, Inc NASDAQ
See more on advanced chartSee more on advanced chart
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
News Ideas Financials Technicals

CLRB Chart

Trade CLRB with trusted brokers on TradingView Open account

Ideas

$CLRB breakout
CLRB
, 1DShort
CLRB: $CLRB breakout

They are presenting at ASCO on June 4th, PT 2$

$CLRB can rise in the next days
CLRB
, 30Long
CLRB: $CLRB can rise in the next days

Contextual immersion trading strategy idea. Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next...

Possible breakout
CLRB
, 1DLong
CLRB: Possible breakout

If clears resistance could hit analysts target.

CLRB
CLRB
, 60Long
CLRB: CLRB

see attached

Long Upside but needs more volume.
CLRB
, 240Long
CLRB: Long Upside but needs more volume.

They have an upside price target of 5.40. There a few resistance points but I will probably set my long term target at the top green marker on the chart. A downfall from time to time is the volume on this stock. Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for...

CLRB Gap Down / Double Bottom Weekly - *ON HIGH ALERT*
CLRB
, 1MLong
CLRB: CLRB Gap Down / Double Bottom Weekly - *ON HIGH ALERT*

This would could be 60-120% gianer if you get in correctly. I am waiting maybe tomorrow or day just depends. I want to know we have a bottom here. LONG.

CLRB chart setup
CLRB
, 1DLong
CLRB: CLRB chart setup

Historical support at 2 dollars. I’m anticipating a bounce.

CLRB Phase 1 Success
CLRB
, 15
CLRB: CLRB Phase 1 Success

Positive news today "CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma". This stock Shs Float is 5.15M, and Market Cap 14.76M.

CLRB going down?
CLRB
, DShort
CLRB: CLRB going down?

CLRB has a buy rating on Zacks Rank, but it has poor financial. Based on my experience (or lack of) studying the graph, I expect the stock will drop in the future. At the moment the stock is $4.08.

CLRB GAP Fill potential
CLRB
, DLong
CLRB: CLRB GAP Fill potential

FDA approval this morning MACD curling

CLRB - Spiker that could spike on Phase 2 data
CLRB
, DLong
CLRB: CLRB - Spiker that could spike on Phase 2 data

Waiting for Phase 2 data to restart the hype for this low floater.

CLRB 1.44 Risk Reward
CLRB
, DLong
CLRB: CLRB 1.44 Risk Reward

Using fib support/resistance

Waiting for the break out.
CLRB
, 60Long
CLRB: Waiting for the break out.

Tech Analysis

Watch for a break about $2.00
CLRB
, 240
CLRB: Watch for a break about $2.00

Market Cap. $ 7,625,400

$CLRB
CLRB
, D
CLRB: $CLRB

wait for flag breakout

Bottoming, Breaking out, and GAP filling in 1 trading day
CLRB
, D
CLRB: Bottoming, Breaking out, and GAP filling in 1 trading day

Very interesting to see this stock bottom, breakout, and GAP fill in 1 trading session.

buy breakup sell breakdown
CLRB
, 15Short
CLRB: buy breakup sell breakdown

it could go either way but mostly down!

pennies to thousands biotech cancer industry
CLRB
, DLong
CLRB: pennies to thousands biotech cancer industry

small cloud but in relative strength strong new hot industry see our book on amazon for selecting stockdsin strong groups cmf increasing should pass cloud soon good volume long narrow base

Technicals

Analyst rating

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Breaking news

More news